article thumbnail

Over-the-Counter Choices Pharmacist Role and Resources

FADIC

OTC drugs come in various forms, including tablets, capsules, creams, and liquids, and are generally labeled with clear instructions on proper usage and dosage. Its OTC drug section covers a broad range of OTC medications, offering detailed descriptions, recommended dosages, and potential drug interactions.

article thumbnail

First paediatric EC approval of HIV drug

European Pharmaceutical Review

At Week two or Week 4, selected participants were given a pharmacokinetic (PK) evaluation to confirm the dosage that the participants would receive. In this study, no new adverse reactions (ARs) have been observed in paediatric subjects aged two years and older living with HIV-1 compared to adults. Treatment cohort 3.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hypertension

RX Note

Resistant Hypertension Resistant hypertension is defined by a patient whose BP is not controlled on three or more drugs (including a diuretic). After excluding medication non-adherence and isolated office hypertension, a quick check on the possible causes of resistant is required.

article thumbnail

US FDA approves AbbVie-Janssen’s Imbruvica for cGVHD in children

Pharmaceutical Technology

The dosage indicated for patients aged one year to under 12 years is once a day, oral 240mg/m2 dose of Imbruvica. Imbruvica's safety was reported to be in line with its established profile and the observed adverse reactions (ARs) were similar to those seen in adults with moderate to severe cGVHD.

article thumbnail

How Long Until AI Starts to Replace Pharmacists

pharmacy mentor

AI algorithms can analyse patient data to predict potential drug interactions, customise treatment plans, and even identify early signs of adverse reactions. Dosage Recommendations : AI tools such as Dosis can analyse patient-specific data (e.g.

article thumbnail

FDA Releases Draft Labeling Guidance for Biosimilar Products

Big Molecule Watch

When information specific to the reference product is described in the biosimilar or interchangeable biosimilar product’s labeling (for example, data from clinical trials of the reference product in the ADVERSE REACTIONS and CLINICAL STUDIES sections), the reference product’s proper name should be used.

article thumbnail

BeiGene’s Brukinsa FDA approved for CLL/SLL

pharmaphorum

The most common adverse reactions noted in the clinical trials of zanubrutinib were neutrophil count decrease (42%), upper respiratory tract infection (39%), platelet count decrease (34%), haemorrhage (30%), and musculoskeletal pain (30%). The median DOR was not reached in either arm, however, after a median follow-up of 14.1